The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
FDA approves patisiran to treat hereditary transthyretin amyloidosis
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2018, Patisiran (ONPATTRO™) gained its approval by the US FDA and became the first marketed RNAi-based therapy.”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [58]
Citations
Cites
Gene-silencing technology gets first drug approval after 20-year wait
Ledford, H. (2018) · Nature · doi:10.1038/d41586-018-05867-7 · Cited by 131
Treatment success in hereditary transthyretin amyloidosis
Fyfe, I. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0048-1 · Cited by 7
Cited by
Sorted by citations
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos‐Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi‐Fainaro, R., Florindo, H. F., & Vicent, M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 715
“No other oligonucleotide-based nanomedicine has been developed and authorized at the same pace, considering, for example, the amyloidosis therapeutic Onpattro® (Patisiran) [10].”
BackgroundWei, T., Cheng, Q., Min, Y.-L., Olson, E. N., & Siegwart, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-17029-3 · Cited by 615
Patel, S., Ashwanikumar, N., Robinson, E., Xia, Y., Mihai, C., Griffith, J. P., Hou, S., Esposito, A. A., Ketova, T., Welsher, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14527-2 · Cited by 601
Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Lu, Y., Chan, Y.-T., Tan, H., Li, S., Wang, N., & Feng, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01197-3 · Cited by 521
“Patisiran Monotherapy Rare polyneuropathy FDA approved [136]”
Background
Metadata
- Authors
- Wood, H.
- Corresponding author
- Wood, Heather
- ORCID
- Wood, Heather
- Venue
- Nature Reviews Neurology
- Published
- 2018-08-29
- Volume
- 14
- Issue
- 10
- Pages
- 570-570
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- OpenAlex
- W2888899523
- Cited by
- 145
- References
- 2
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 12 · 2023: 22 · 2022: 14 · 2021: 23 · 2020: 20 · 2019: 28 · 2018: 5
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- patisiran, hereditary transthyretin amyloidosis, RNA interference therapy, prealbumin, FDA drug approval, rare genetic disorders, antisense oligonucleotides, protein misfolding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
